A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer-Reference-Cited by-同舟云学术

A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer

Published:2023-01 Issue:1 Volume:209 Page:121-130
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Tsung Irene¹^ORCID,Green Edward¹,Palmbos Phillip¹,Sloan Zachery²,Reichert Zachery R.¹,Vaishampayan Ulka¹,Smith David C.¹,Caram Megan E. V.¹,Yentz Sarah¹,Daignault-Newton Stephanie²,Hurley Laura²,Nguyen Charles B.¹,Kraft Shawna³,Alva Ajjai¹

Affiliation:

1. Department of Hematology and Oncology, Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan

2. Oncology Clinical Trials Support Unit, Rogel Comprehensive Cancer Center, Ann Arbor, Michigan

3. Department of Pharmacy, University of Michigan, Ann Arbor, Michigan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Link

http://www.auajournals.org/doi/pdf/10.1097/JU.0000000000002969

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma;Cancer Research Communications;2024-02-26

2. All-cause and immune checkpoint inhibitor–associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality;Clinical Kidney Journal;2023-11-28

3. Clinical outcomes of immune checkpoint inhibitor plus nab-paclitaxel in metastatic upper tract urothelial carcinoma;Translational Andrology and Urology;2023-09